Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

ntent/@epidemiologysurveilance/documents/document/acspc-028323.pdf. Accessed on October 24, 2011.

[iv] National Cancer Institute. Colon and Rectal Cancer. Available at: http://www.cancer.gov/cancertopics/types/colon-and-rectal. Accessed on October 24, 2011.

[v] National Cancer Institute. Stage IV and Recurrent Colon Cancer. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page9. Accessed on October 24, 2011.

[vi] S. Wilhelm, et al. Regorafenib (Bay 73-4506): A New Oral Multikinase Inhibitor of Angiogenic, Stromal, and Oncogenic Receptor Tyrosine Kinases with Potent Preclinical Antitumor Activity. Online International Journal of Cancer. December 17, 2010.

 

 


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  New York College of Health Professions announces ... portfolio with U.S. Patent #8,996,098 donated by its Chairman ... a surgical instrument that allows surgeons to view and ... in the traditional format of a slide that is ... during surgery, thus providing the surgeon real time analysis ...
(Date:4/1/2015)... ASPEN, Colo. , April 1, 2015  Astellas ... (CKF), is pleased to sponsor the second annual Bounce ... award, which will recognize two transplant recipients who exhibit ... a career accomplishment, participation in a sport or hobby, ... loved ones. "The Bounce Back Award ...
(Date:4/1/2015)... 2015  The fairness of the proposed acquisition of ... Pharmaceutical Industries ("Teva") is being investigated by WeissLaw LLP, ... investigation focuses on possible breaches of fiduciary duty and ... of ASPX for agreeing to sell the Company to ... definitive agreement for Teva to acquire ASPX in a ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2
... Recent Highlights: Qutenza ® (capsaicin) ... adoption by large US institutions; 238 hospitals purchased as of 4Q10, ... Q4 2010 revenue totaled $2.3 million including $0.5 million U.S. Qutenza ... in 17 countries at December 31, 2010 NGX-1998 Phase 2 ...
... March 30, 2011 Rochester Medical Corporation (Nasdaq: ... BioSciences N.V. today approved the previously announced sale of ... subsidiary to Rochester Medical Corporation. Rochester Medical ... and under the terms of the Share Purchase Agreement ...
Cached Medicine Technology:NeurogesX Reports Fourth Quarter and Year-End 2010 Results 2NeurogesX Reports Fourth Quarter and Year-End 2010 Results 3NeurogesX Reports Fourth Quarter and Year-End 2010 Results 4NeurogesX Reports Fourth Quarter and Year-End 2010 Results 5NeurogesX Reports Fourth Quarter and Year-End 2010 Results 6NeurogesX Reports Fourth Quarter and Year-End 2010 Results 7NeurogesX Reports Fourth Quarter and Year-End 2010 Results 8NeurogesX Reports Fourth Quarter and Year-End 2010 Results 9Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation 2
(Date:4/1/2015)... ON (PRWEB) April 01, 2015 It all ... founder Patricia Di Gasbarro, who was on a mission to ... pure and simple ingredients that parents could trust. Now, Shoosha ... Food Grade Organic skincare products, meaning all products contain a ... North America. , Babies’ skin is considered to be 40% ...
(Date:4/1/2015)... SCI Solutions , the health ... announced that CEO Joel French will be a featured ... Exhibition in Chicago, April 12-16, 2015. French will ... Care Coordination Strategies ” with Northeast Georgia Health System ... More than 38,000 healthcare industry professionals are expected at ...
(Date:4/1/2015)... San Diego, CA (PRWEB) April 01, 2015 ... promotion organization, is announcing two continuing medical education ... goal is to help practitioners become more confident ... to prevent disease. After completion of these CME ... , The CME courses available are ...
(Date:4/1/2015)... 01, 2015 Like a mosaic slowly ... scientific understanding of the potential causes of rosacea. April ... National Rosacea Society (NRS) to educate the public on ... disorder now estimated to affect more than 16 million ... research on rosacea through its patient-funded research grants program, ...
(Date:4/1/2015)... April 01, 2015 Health Advocate™, Inc., ... a subsidiary of West Corporation, today launched its new ... http://blog.healthadvocate.com and through the Health Advocate member website, ... get, and stay, healthy. , “We’re pleased to introduce ... the public,” said Martin Rosen, Executive Vice President, Health ...
Breaking Medicine News(10 mins):Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 2Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:Health Advocate Launches New Health and Wellness Blog 2
... Million Fundraising Campaign for Dallas Center for the ... Health Care System Foundation announced today the appointment ... In this role, Lively will offer counsel in ... philanthropic plan for Baylor. Initially, he will offer ...
... Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... as the Company,s Acting Chief Executive Officer. Mr. ... February 2007. With the Acting CEO appointment, the ... search for a permanent, full-time president and chief ...
... Science,(Nasdaq: CSCX ), a global leader ... completed a three-year agreement for,product design and engineering ... firm serving the medical devices industry. , ... , "We expect considerable ...
... WASHINGTON, Feb. 4 "Patients, nurses, and the Broadlands,neighborhood ... was,denied," said Kathy McGregor, RN, an organizer with the ... RNs at hospitals across the country. , ... of cutting corners on patient care,in the name of ...
... MI based manufacturer of industrial parts cleaning systems and custom ... field. Midbrook’s Cart Washer for Central Processing was ... for Central Processing is a large capacity, fully automated, floor ... Processing Unit of hospitals. , ...
... every Monday "Wear Red" Day , ... (PRWEB) February 4, 2009 -- ... of dying from heart disease. About ten times as many women ... year, yet an astonishing 90 percent of primary care doctors still don,t ...
Cached Medicine News:Health News:Bill Lively Joins Baylor Health Care System Foundation as Senior Strategic Development Consultant 2Health News:Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO 2Health News:Cardiac Science Increases R&D Capacity With 3-year Syncroness Agreement 2Health News:Cardiac Science Increases R&D Capacity With 3-year Syncroness Agreement 3Health News:Midbrook Installs New Cart Washer for Central Processing in Local Hospital 2Health News:'Go Red for Women' Gets Stronger by the Week 2
... safely provides effective air warming therapy to ... design of our WarmAir® FilteredFlo® blankets, we ... supplies gently moving, clean air that minimizes ... to your patient or staff. All air ...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Inquire...
Medicine Products: